Showing results (61-70 of 453) with videos related to
Sort By:
Pageof 46
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.Cancer Biology & Medicine|July 27, 2016
Immuno-oncology combinations: raising the tail of the survival curveSamuel J Harris, Jessica Brown, Juanita Lopez, et al.Cancer Discovery|July 3, 2016
CDK4/6 Inhibitors: Promising Opportunities beyond Breast CancerJoline S J Lim, Nicholas C Turner, Timothy A YapChinese Journal of Cancer|May 7, 2013
Targeting the PI3K-AKT-mTOR signaling network in cancerKhurum H Khan, Timothy A Yap, Li Yan, et al.British Journal of Cancer|December 17, 2020
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage responseNiamh Coleman, Bingnan Zhang, Lauren A Byers, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2016
Combining Molecularly Targeted Agents: Is More Always Better?Raghav Sundar, Nicola Valeri, Kevin J Harrington, et al.Current Opinion in Pharmacology|June 29, 2015
Drugging PI3K in cancer: refining targets and therapeutic strategiesTimothy A Yap, Lynn Bjerke, Paul A Clarke, et al.Cancer Discovery|June 4, 2017
Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination StrategiesRaghav Sundar, David S Hong, Scott Kopetz, et al.American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and BeyondTimothy A Yap, Ruth Plummer, Nilofer S Azad, et al.Pageof 46